Simhandl C, Denk E, Thau K
University Clinic of Vienna, Department of Psychiatry, Austria.
J Affect Disord. 1993 Aug;28(4):221-31. doi: 10.1016/0165-0327(93)90057-q.
The prophylactic efficacy of carbamazepine slow release (CBZ) at ke different blood levels and lithium carbonate slow release (LI) was compared in a retrospective/prospective, randomized, 2-year open trial. 84 patients with a DSM-III-R diagnosis of recurrent affective disorder who had no prophylactic medication in the 2 years preceding the trial (no LI nonresponders), were randomly allocated to three treatment groups: CBZ low (15-25 mumol/l), CBZ high (28-40 mumol/l) and LI (0.6-0.8 mumol/l). Fifty-eight patients completed the full observation period of 2 years, 26 patients dropped out. There were no statistically significant differences in the efficacy of the prophylactic treatment for bipolar patients. For the unipolar patients, the group with a low CBZ serum level showed no reduction in the duration of episodes. The two other treatment groups seem to be equal in attenuation of a unipolar course of an affective disorder.
在一项回顾性/前瞻性、随机、为期2年的开放试验中,比较了不同血药浓度的缓释卡马西平(CBZ)和缓释碳酸锂(LI)的预防效果。84例符合DSM-III-R诊断标准的复发性情感障碍患者,在试验前2年未接受过预防性药物治疗(无LI无反应者),被随机分为三个治疗组:低剂量CBZ组(15 - 25 μmol/l)、高剂量CBZ组(28 - 40 μmol/l)和LI组(0.6 - 0.8 μmol/l)。58例患者完成了2年的完整观察期,26例患者退出。双相情感障碍患者预防性治疗的疗效无统计学显著差异。对于单相情感障碍患者,低CBZ血清水平组的发作持续时间没有缩短。其他两个治疗组在减轻单相情感障碍病程方面似乎效果相当。